# Nagisa

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nagisa

- Industry: Software
- Headquarters: Tokyo, Japan
- Website: https://nagisa-inc.jp
- Total disclosed funding: $2.7M
- Latest round: Series A (Dec 4, 2023)
- Investors on record: 3

## About

Nagisa, Inc. is a Japan-based company focused on biotechnology, specializing in the development of advanced cell culture products and diagnostic tools to support research and therapeutic applications.Nagisa, Inc. was founded in 2010 in Tokyo, Japan, and specializes in biotechnology solutions. The company has completed 6 deals to date, with its most recent funding round being a Series A, raising JPY 400 million on December 4, 2023, from investors like Mint, Money Forward Venture Partners, and W Fund. The total amount raised by Nagisa to date stands at JPY 400 million, with a current company valuation of JPY 1,411.953 million.Nagisa Inc. specializes in developing advanced solutions within the biotechnology sector, focusing primarily on cell culture products and diagnostic tools. Their flagship offerings include a range of cell culture media designed to support the growth and maintenance of various cell types for research and therapeutic applications. These products are employed extensively by researchers in academic institutions, pharmaceutical companies, and biotechnology firms, facilitating advancements in drug development and regenerative medicine. Additionally, Nagisa Inc. provides diagnostic kits that enable precise cellular analysis, addressing critical needs in clinical diagnostics and research environments. The company's products are marketed primarily in North America and parts of Europe, catering to a diverse clientele that includes academic researchers, healthcare professionals, and biotech enterprises.Nagisa Inc. generates revenue through a structured model that includes direct sales of its specialized products as well as potential partnerships with research institutions and pharmaceutical companies. The company primarily engages in B2B transactions, where clients purchase cell culture media and diagnostic kits tailored to specific research needs. These engagements may involve volume-based pricing plans that reward larger orders, enhancing client loyalty and ensuring a stable revenue stream. In addition to direct sales, Nagisa Inc. may also explore collaborative ventures for product development, thereby expanding its market reach and reinforcing its position within the biotechnology landscape. The transaction structure emphasizes long-term relationships with clients, fostering recurring revenue opportunities through subscriptions for ongoing supply needs or specialized service agreements.In December 2023, Nagisa, Inc. raised JPY 400 million in Series A funding to develop new products, recruit talent, and strengthen its management base. The company plans to design and launch innovative cell culture products, with releases expected in the coming year. Furthermore, Nagisa aims to expand its market presence into new regions, specifically targeting additional markets in Europe and North America by 2025. This funding will be pivotal in supporting these initiatives and reinforcing Nagisa's strategic growth.

## Funding rounds

- Series A, Dec 4, 2023, $2.7M — Mint, Money Forward Venture Partners, W Fund

## Investors

- Mint (https://capitalatlas.ai/funds/mint) — Series A
- Money Forward Venture Partners (https://capitalatlas.ai/funds/money-forward-venture-partners) — Series A
- W Fund (https://capitalatlas.ai/funds/w-fund) — Series A